HK1167999A1 - 酸性神經酰胺酶的向溶酶體抑制劑 - Google Patents
酸性神經酰胺酶的向溶酶體抑制劑Info
- Publication number
- HK1167999A1 HK1167999A1 HK12108760.7A HK12108760A HK1167999A1 HK 1167999 A1 HK1167999 A1 HK 1167999A1 HK 12108760 A HK12108760 A HK 12108760A HK 1167999 A1 HK1167999 A1 HK 1167999A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lysosomotropic
- inhibitors
- acid ceramidase
- ceramidase
- acid
- Prior art date
Links
- 102000006772 Acid Ceramidase Human genes 0.000 title 1
- 108020005296 Acid Ceramidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002080 lysosomotropic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11185208P | 2008-11-06 | 2008-11-06 | |
PCT/US2009/063586 WO2010054223A1 (en) | 2008-11-06 | 2009-11-06 | Lysosomotropic inhibitors of acid ceramidase |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1167999A1 true HK1167999A1 (zh) | 2012-12-21 |
Family
ID=42153265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12108760.7A HK1167999A1 (zh) | 2008-11-06 | 2012-09-07 | 酸性神經酰胺酶的向溶酶體抑制劑 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8697379B2 (zh) |
EP (1) | EP2348839B1 (zh) |
JP (1) | JP5721631B2 (zh) |
CN (1) | CN102368905B (zh) |
AU (1) | AU2009313400A1 (zh) |
BR (1) | BRPI0921278A2 (zh) |
CA (1) | CA2742866C (zh) |
HK (1) | HK1167999A1 (zh) |
RU (1) | RU2011117722A (zh) |
WO (1) | WO2010054223A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050265A2 (en) * | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
WO2006050264A1 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
WO2010054223A1 (en) | 2008-11-06 | 2010-05-14 | Musc Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
AU2009332952A1 (en) * | 2008-12-30 | 2011-07-21 | Musc Foundation For Research Development | Sphingo-guanidines and their use as inhibitors of sphingosine kinase |
ES2791760T3 (es) | 2011-09-07 | 2020-11-05 | Sinai School Medicine | Ceramidasa y diferenciación celular |
ITMI20120923A1 (it) | 2012-05-28 | 2013-11-29 | Fond Istituto Italiano Di Tec Nologia 45 | Inibitori della ceramidasi acida e loro usi come medicamenti |
ITMI20120921A1 (it) | 2012-05-28 | 2013-11-29 | Fond Istituto Italiano Di Tec Nologia 45 | Inibitori della ceramidasi acida e loro usi come medicamenti |
WO2013181530A1 (en) * | 2012-06-01 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
EP2968479B1 (en) | 2013-03-14 | 2019-07-17 | Icahn School of Medicine at Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
WO2015119393A1 (ko) * | 2014-02-04 | 2015-08-13 | (주)네오팜 | 발모촉진용 또는 탈모방지용 조성물 |
KR20150091983A (ko) * | 2014-02-04 | 2015-08-12 | (주)네오팜 | 발모촉진용 또는 탈모방지용 조성물 |
WO2015173168A1 (en) | 2014-05-12 | 2015-11-19 | Fondazione Istituto Italiano Di Tecnologia | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
WO2015173169A1 (en) | 2014-05-12 | 2015-11-19 | Fondazione Istituto Italiano Di Tecnologia | Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
WO2018200931A1 (en) * | 2017-04-28 | 2018-11-01 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
CN110598636B (zh) * | 2019-09-09 | 2023-01-17 | 哈尔滨工业大学 | 一种基于特征迁移的舰船目标识别方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2515465A (en) | 1946-03-22 | 1950-07-18 | Merck & Co Inc | Preparation of 2-alkyl-4-isopropylidene-5(4)-oxazolones |
GB630712A (en) | 1946-03-22 | 1949-10-19 | Merck & Co Inc | Process of preparing intermediates useful in the preparation of penicill amine |
GB844431A (en) * | 1957-12-07 | 1960-08-10 | Boehringer & Soehne Gmbh | Injectable aqueous solutions of chloramphenicol |
US3466292A (en) | 1966-05-13 | 1969-09-09 | Upjohn Co | Diazatricyclododecanediones and diazatricyclododecadiendiones |
GB1307539A (en) * | 1970-06-25 | 1973-02-21 | Smith Kline French Lab | Thiourea derivatives |
US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
DE2408813A1 (de) | 1974-02-23 | 1975-09-04 | Agfa Gevaert Ag | N-carbamoyloxypyridiniumsalze und verfahren zur herstellung derselben |
US4481203A (en) | 1977-04-05 | 1984-11-06 | Taiho Pharmaceutical Company, Limited | Composition containing 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil |
DE2817494A1 (de) | 1977-05-03 | 1978-11-09 | Continental Pharma | Aminoalkohol-derivat |
US4151198A (en) | 1978-06-02 | 1979-04-24 | American Cyanamid Company | Resolution of N-acyl-DL (+)-phenylalanines |
US4283541A (en) | 1980-05-27 | 1981-08-11 | Usv Pharmaceutical Corporation | Pyridylacyl-hydroxamates |
US4544670A (en) | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
EP0310545A3 (de) | 1987-09-02 | 1989-07-26 | Ciba-Geigy Ag | Cyanoguanidine als Härter für Epoxidharze |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5679350A (en) | 1992-05-28 | 1997-10-21 | The University Of Toledo | Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material |
US5369030A (en) | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
WO1995006037A1 (en) * | 1993-08-27 | 1995-03-02 | Vrije Universiteit | New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor |
WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US5830916A (en) | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
DE19621038A1 (de) | 1996-05-24 | 1997-11-27 | Boehringer Ingelheim Kg | Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten |
US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
AU765809B2 (en) | 1998-02-12 | 2003-10-02 | Emory University | Sphingolipid derivatives and their methods of use |
EP1127075A2 (en) | 1998-11-06 | 2001-08-29 | MUSC Foundation For Research Development | A method of treating tumors using fas-induced apoptosis |
WO2001079152A1 (en) | 2000-04-19 | 2001-10-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US6756504B2 (en) | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US6696081B2 (en) | 2000-06-09 | 2004-02-24 | Duke University | Carbohydrate based lipid compositions and supramolecular structures comprising same |
CN1744919A (zh) | 2000-09-11 | 2006-03-08 | 南卡罗莱纳医科大学研究发展基金会 | 使用凋亡的选择性诱导来治疗肿瘤的方法和组合物 |
WO2003005965A2 (en) | 2001-07-11 | 2003-01-23 | Musc Foundation For Research Development | Modulators of ceramidase and methods of use based thereon |
JP2004210733A (ja) * | 2003-01-07 | 2004-07-29 | Kyowa Hakko Kogyo Co Ltd | アリールスルファマート誘導体 |
MXPA05005664A (es) * | 2003-01-27 | 2005-07-27 | Pfizer Prod Inc | Derivados de isotiazol. |
CA2516250A1 (en) | 2003-02-19 | 2004-09-02 | Endacea, Inc. | A1 adenosine receptor antagonists |
EP1707211A4 (en) * | 2003-11-28 | 2009-08-05 | Takara Bio Inc | Ceramidase INHIBITORS |
KR100822530B1 (ko) | 2004-03-05 | 2008-04-16 | 에프. 호프만-라 로슈 아게 | P2x3 및 p2x2/3 길항물질로서의 다이아미노피리미딘 |
JP2005336174A (ja) * | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 変形性関節症治療剤 |
WO2006050264A1 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
WO2006050265A2 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
JP2006298807A (ja) * | 2005-04-19 | 2006-11-02 | Lead Chemical Co Ltd | 新規化合物及びその用途 |
BRPI0611966B1 (pt) | 2005-06-17 | 2022-05-03 | Apogee Biotechnology Corporation | Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo |
WO2007117400A2 (en) * | 2006-03-31 | 2007-10-18 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
CN101600686A (zh) * | 2006-12-13 | 2009-12-09 | 先灵-普劳有限公司 | 氯霉素、甲砜霉素及其类似物的水溶性前药 |
WO2010054223A1 (en) | 2008-11-06 | 2010-05-14 | Musc Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
AU2009332952A1 (en) | 2008-12-30 | 2011-07-21 | Musc Foundation For Research Development | Sphingo-guanidines and their use as inhibitors of sphingosine kinase |
-
2009
- 2009-11-06 WO PCT/US2009/063586 patent/WO2010054223A1/en active Application Filing
- 2009-11-06 RU RU2011117722/13A patent/RU2011117722A/ru not_active Application Discontinuation
- 2009-11-06 JP JP2011535698A patent/JP5721631B2/ja active Active
- 2009-11-06 AU AU2009313400A patent/AU2009313400A1/en not_active Abandoned
- 2009-11-06 US US13/127,888 patent/US8697379B2/en not_active Expired - Fee Related
- 2009-11-06 BR BRPI0921278-7A patent/BRPI0921278A2/pt not_active Application Discontinuation
- 2009-11-06 CN CN200980154007.6A patent/CN102368905B/zh not_active Expired - Fee Related
- 2009-11-06 CA CA2742866A patent/CA2742866C/en not_active Expired - Fee Related
- 2009-11-06 EP EP09825496.4A patent/EP2348839B1/en active Active
-
2012
- 2012-09-07 HK HK12108760.7A patent/HK1167999A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2012508249A (ja) | 2012-04-05 |
CA2742866C (en) | 2017-10-24 |
WO2010054223A1 (en) | 2010-05-14 |
CN102368905B (zh) | 2015-04-01 |
CA2742866A1 (en) | 2010-05-14 |
BRPI0921278A2 (pt) | 2015-08-25 |
EP2348839A1 (en) | 2011-08-03 |
US20110251197A1 (en) | 2011-10-13 |
RU2011117722A (ru) | 2012-12-20 |
AU2009313400A1 (en) | 2010-05-14 |
EP2348839B1 (en) | 2017-04-05 |
CN102368905A (zh) | 2012-03-07 |
JP5721631B2 (ja) | 2015-05-20 |
US8697379B2 (en) | 2014-04-15 |
EP2348839A4 (en) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1167999A1 (zh) | 酸性神經酰胺酶的向溶酶體抑制劑 | |
PL2178840T3 (pl) | Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh | |
HK1156306A1 (zh) | 作為 -脯氨酰基- -羥化酶抑制劑的取代的二氫吡唑啉酮類化合物 | |
IL216383A0 (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
EP2249650A4 (en) | ANILINOPYRIDINE AS A FAK HEMMER | |
HK1161680A1 (zh) | 作為 抑制劑的吡唑基氨基吡啶 | |
HRP20171390T1 (hr) | Inhibitor tolerancije na analgetike | |
IL208212A0 (en) | Hydroxamate-based inhibitors of deacetylases b | |
LT2506840T (lt) | Hipoksija sukeliančio faktoriaus inhibitorių naudojimas | |
IL208916A0 (en) | Inhibitors of jnk | |
IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
GB0803895D0 (en) | Inhibitors of glyoxalase | |
ZA201000383B (en) | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | |
GB0908609D0 (en) | New use of isoQC inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE CHINESE NAME OF INVENTOR FROM Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20201104 |